Cetera Advisor Networks LLC decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.6% during the third quarter, according to its most recent filing with the SEC. The firm owned 149,528 shares of the company’s stock after selling 2,475 shares during the period. Johnson & Johnson comprises about 0.9% of Cetera Advisor Networks LLC’s holdings, making the stock its 22nd largest holding. Cetera Advisor Networks LLC’s holdings in Johnson & Johnson were worth $19,480,000 at the end of the most recent reporting period.
Several other hedge funds have also recently bought and sold shares of the business. Vanguard Group Inc. lifted its holdings in shares of Johnson & Johnson by 1.5% during the 2nd quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock valued at $26,517,661,000 after buying an additional 3,023,110 shares during the period. BlackRock Inc. raised its holdings in Johnson & Johnson by 2.6% in the 2nd quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock worth $23,028,219,000 after purchasing an additional 4,332,612 shares during the period. Bank of New York Mellon Corp raised its holdings in Johnson & Johnson by 0.4% in the 3rd quarter. Bank of New York Mellon Corp now owns 36,594,054 shares of the company’s stock worth $4,757,593,000 after purchasing an additional 130,437 shares during the period. FMR LLC raised its holdings in Johnson & Johnson by 5.9% in the 2nd quarter. FMR LLC now owns 27,237,648 shares of the company’s stock worth $3,603,268,000 after purchasing an additional 1,509,745 shares during the period. Finally, Capital World Investors raised its holdings in Johnson & Johnson by 4.1% in the 2nd quarter. Capital World Investors now owns 26,510,007 shares of the company’s stock worth $3,507,009,000 after purchasing an additional 1,050,000 shares during the period. Hedge funds and other institutional investors own 67.23% of the company’s stock.
In other Johnson & Johnson news, VP Paulus Stoffels sold 155,342 shares of the company’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $129.86, for a total value of $20,172,712.12. Following the completion of the transaction, the vice president now owns 357,906 shares in the company, valued at $46,477,673.16. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.22% of the stock is currently owned by corporate insiders.
Shares of JNJ traded down $2.61 during trading hours on Friday, reaching $128.10. 6,385,117 shares of the company traded hands, compared to its average volume of 8,128,365. The firm has a market capitalization of $349,877.28, a PE ratio of 17.55, a price-to-earnings-growth ratio of 2.07 and a beta of 0.74. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.41 and a quick ratio of 1.12. Johnson & Johnson has a 12-month low of $120.95 and a 12-month high of $148.32.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, January 23rd. The company reported $1.74 earnings per share for the quarter, beating analysts’ consensus estimates of $1.72 by $0.02. Johnson & Johnson had a net margin of 1.70% and a return on equity of 29.00%. The firm had revenue of $20.20 billion for the quarter, compared to analyst estimates of $20.08 billion. During the same period in the previous year, the company earned $1.58 earnings per share. The business’s quarterly revenue was up 11.5% compared to the same quarter last year. research analysts anticipate that Johnson & Johnson will post 8.11 EPS for the current fiscal year.
A number of equities research analysts have commented on the company. Vetr raised Johnson & Johnson from a “hold” rating to a “buy” rating and set a $150.89 price target on the stock in a report on Thursday, January 11th. Stifel Nicolaus raised their price objective on Johnson & Johnson from $142.00 to $145.00 and gave the company a “hold” rating in a research report on Wednesday, January 24th. BMO Capital Markets raised their price objective on Johnson & Johnson to $161.00 and gave the company an “outperform” rating in a research report on Tuesday, December 12th. Jefferies Group set a $161.00 price objective on Johnson & Johnson and gave the company a “buy” rating in a research report on Friday, March 23rd. Finally, TheStreet lowered Johnson & Johnson from an “a” rating to a “c+” rating in a research report on Monday, March 26th. Five analysts have rated the stock with a sell rating, eight have given a hold rating and nine have issued a buy rating to the company’s stock. Johnson & Johnson has a consensus rating of “Hold” and an average price target of $144.58.
ILLEGAL ACTIVITY NOTICE: This report was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/07/johnson-johnson-jnj-position-trimmed-by-cetera-advisor-networks-llc.html.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.